geranylgeraniol has been researched along with Osteosarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, HL; Hsieh, MJ; Lin, CW; Lu, KH; Yang, JS; Yang, SF | 1 |
1 other study(ies) available for geranylgeraniol and Osteosarcoma
| Article | Year |
|---|---|
Zoledronate blocks geranylgeranylation not farnesylation to suppress human osteosarcoma U2OS cells metastasis by EMT via Rho A activation and FAK-inhibited JNK and p38 pathways.
Topics: Biological Transport; Bone Density Conservation Agents; Bone Neoplasms; Cadherins; cdc42 GTP-Binding Protein; Cell Line, Tumor; Cell Movement; Cell Survival; Diphosphonates; Diterpenes; Epithelial-Mesenchymal Transition; Farnesol; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Neoplasm Invasiveness; Nuclear Proteins; Osteoporosis; Osteosarcoma; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prenylation; Proto-Oncogene Proteins pp60(c-src); rho-Associated Kinases; Snail Family Transcription Factors; Twist-Related Protein 1; Zoledronic Acid | 2016 |